Presently, the primary indicators employed for assessing the responsiveness of patients to immunotherapy primarily include the expression of PD-1/PD-L1 and the tumor mutational burden (TMB); however, the predictive capacity of these indicators is limited and requires further investigation. Here, CD274 is linked to neoplasm.